BioSense
BioSense, a subsidiary of Johnson & Johnson’s MedTech division, specializes in cardiac arrhythmia treatment technologies, particularly in the field of electrophysiology.
Profile
Develops and markets advanced cardiac ablation technologies for treating arrhythmias.
BioSense, a subsidiary of Johnson & Johnson’s MedTech division, specializes in cardiac arrhythmia treatment technologies, particularly in the field of electrophysiology. Founded as part of Johnson & Johnson’s broader medical device portfolio, BioSense has grown into a global leader in cardiac ablation products, with a focus on reducing fluoroscopy use during procedures. The company’s flagship product, the CARTO 3 mapping and navigation system, is widely adopted in electrophysiology labs worldwide.
In 2023, BioSense received FDA approval for its zero-fluoroscopy workflow, enabling safer and more efficient cardiac ablation procedures. The company’s financial trajectory remains robust, supported by Johnson & Johnson’s extensive R&D and global distribution network. Recent innovations include the VARIPULSE Pro platform, launched in Europe in 2026, which introduces a faster pulse sequence for pulsed field ablation procedures.
BioSense’s commitment to real-world evidence generation, as seen in the REAL AF Registry, underscores its focus on advancing cardiac care. However, the company faces legal challenges, including a $147M antitrust verdict in 2025 favoring Innovative Health, which accused BioSense of anti-competitive practices.
Who buys this
- Hospitals with electrophysiology labs
- Cardiologists and electrophysiologists
- Medical device distributors
- Healthcare systems specializing in cardiac care
Strengths and what to watch
Strengths
- Global leader in cardiac ablation technologies with a strong market position
- Integration with Johnson & Johnson’s extensive R&D and distribution network
- Commitment to reducing fluoroscopy use, improving patient and clinician safety
Watch for
- Legal challenges, including a $147M antitrust verdict in 2025
- Dependence on Johnson & Johnson’s broader MedTech strategy
- Competition from emerging pulsed field ablation technologies
Recent moves
Key Information
- Founded
- 2020
- Headquarters
- Thane, Maharashtra
Frequently Asked Questions
What does BioSense Webster specialize in?
BioSense Webster, a Johnson & Johnson subsidiary, develops advanced cardiac ablation technologies for treating arrhythmias. Their CARTO 3 mapping system and zero-fluoroscopy workflow, FDA-approved in 2023, are widely used in electrophysiology labs globally. The company focuses on safer ablation procedures through innovative navigation and pulsed field technologies.
What is the VARIPULSE Pro platform?
Launched in Europe in 2026, VARIPULSE Pro is BioSense's latest pulsed field ablation system offering faster treatment sequences. This platform builds on their CARTO 3 technology, enhancing precision in cardiac arrhythmia procedures while maintaining the company's commitment to reducing fluoroscopy use during ablation treatments.
How does BioSense's zero-fluoroscopy technology work?
BioSense's FDA-approved workflow uses advanced 3D mapping instead of traditional X-ray guidance during cardiac ablation. The CARTO 3 system creates real-time heart models, allowing physicians to navigate catheters precisely without radiation exposure. This innovation improves safety for both patients and medical staff during electrophysiology procedures.
What legal challenges has BioSense faced?
In 2025, BioSense lost a $147M antitrust lawsuit filed by Innovative Health, which alleged anti-competitive practices. This verdict highlights ongoing legal pressures in the cardiac ablation market, though BioSense maintains operations through Johnson & Johnson's support and continues product development.
Who uses BioSense Webster's products?
Major hospitals with electrophysiology labs, cardiologists, and healthcare systems specializing in cardiac care rely on BioSense's technologies. Their products are distributed globally through Johnson & Johnson's network, serving medical professionals who perform complex arrhythmia treatments requiring precise ablation capabilities.
What's new with BioSense Webster's technology?
Recent developments include the 2026 European launch of VARIPULSE Pro for pulsed field ablation and the 2023 FDA-approved zero-fluoroscopy workflow. These innovations demonstrate BioSense's focus on advancing cardiac care through safer, more efficient ablation technologies while facing competition in this rapidly evolving medical sector.
Sources
- www.businesswire.com — Launch of VARIPULSE Pro in Europe
- www.businesswire.com — $147M antitrust verdict against BioSense
- www.prnewswire.com — FDA approval for zero-fluoroscopy workflow
- www.prnewswire.com — Acquisition of NuVera Medical by BioSense